Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Anika Therapeutics Q4 2023 Adj EPS $0.05 Beats $(0.26) Estimate, Sales $42.971M Beat $41.405M Estimate

Author: Benzinga Newsdesk | March 13, 2024 04:36pm
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.26) by 119.23 percent. This is a 123.81 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $42.971 million which beat the analyst consensus estimate of $41.405 million by 3.78 percent. This is a 8.45 percent increase over sales of $39.622 million the same period last year.

Posted In: ANIK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist